Last reviewed · How we verify
NCT06246045: ASCENT
Artificial Intelligence to StrategiCally Enhance Pulmonary Embolism Response Team Activation
NA trial testing Walking test in Pulmonary Embolism Subacute Massive. Withdrawn.
1 January 2026
Quick facts
| Lead sponsor | University Hospitals Cleveland Medical Center |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 January 2025 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Walking test
Conditions studied
- Pulmonary Embolism Subacute Massive — all drugs for Pulmonary Embolism Subacute Massive →
Sponsor
University Hospitals Cleveland Medical Center
Who can join
Adults 18 to 99, any sex, with Pulmonary Embolism Subacute Massive. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pulmonary embolism (PE) remains a high mortality and morbidity disease state. The investigators have previously shown that use of a Pulmonary Embolism Response Team (PERT) can improve overall readmission, bleeding, and mortality outcomes. Unfortunately, PERT may still be underutilized from a national standpoint and may not be readily available in underserved areas. The use of artificial intelligence (AI) may help streamline and systematically ensure unbiased mechanism for activation of PERT for discussion of patients with siginficant clot burden and hemodynamic abnormalities. AI algorithms have been FDA approved for use of triage of the PE patient. The institutional PERT program will adapt the use of an AI algorithm for activation as routine care; the efficiency of activation will be compared to our retrospective historical comparison for efficiency and appropriateness of activation. The active phase of the study is designed to further differentiate between patients who are considered to be intermediate-high risk category but yet do not clearly qualify for invasive therapy (catheter-directed therapy, systemic thrombolysis, or invasive hemodynamic support). These patients will undergo walking test to further understand noninvasive hemodynamic compromise and undergo 2:1 randomization to early-invasive strategy versus mtranditional medical therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06246045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Walking test
Trials testing the same drug.
- NCT05908279 — Gait Control in Parkinson Disease · recruiting
- NCT05492604 — Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP. · NA · completed
- NCT03319264 — Sarcopenia in Axial and Peripheral Spondyloarthropathies · NA · completed
Other recruiting trials for Pulmonary Embolism Subacute Massive
Currently open trials in the same condition.
- NCT07029841 — Cohort Study on Treatment Comes of Catheter-based Therapy in Patients With Acute Pulmonary Embolism in Hong Kong · recruiting
Other University Hospitals Cleveland Medical Center trials
Trials by the same sponsor.
- NCT06997198 — Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · Phase 4 · not yet recruiting
- NCT07379814 — Rectus Abdominis Detrusor Myoplasty for Urinary Retention · not yet recruiting
- NCT07499648 — Baby Steps to Care · NA · not yet recruiting
- NCT07497737 — OMT for Adhesive Capsulitis · Phase 4 · not yet recruiting
- NCT06523166 — Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06246045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Cleveland Medical Center
- Last refreshed: 23 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06246045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing